person · Reporting owner

Westphal Christoph H

Disclosed activity across 2 companies

Tapewire entity: 137122
SEC CIK: 0001291961

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
TScan Therapeutics, Inc.TCRX · Entity 7255	10% owner	July 20, 2021	July 22, 2021

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

TScan Therapeutics, Inc.

Report date July 20, 2021 · Filed July 22, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Voting Common StockSEC Table I · non-derivative	IndirectSee footnote	1,145,505	Reported balance After 2021-07-20 transaction · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · 2021-07-20 · Conversion · Acquired 1,145,505 · Balance 1,145,505 F2: Each share of the Issuer's preferred stock automatically converted on a one for one basis into Voting Common Stock immediately prior to the closing of the Issuer's initial public offering, without payment or further consideration. The preferred stock had no expiration date. F3: These shares are held by Longwood Fund IV, L.P. ("Longwood"). The general partner of Longwood is Longwood Fund IV GP, LLC ("Longwood GP"). Voting, investment and dispositive decisions at Longwood GP with respect to the securities held by Longwood are made by an investment committee comprised of Christoph Westphal, Richard Aldrich and John Lawrence (collectively, the "IC Members"). Longwood GP and each of the IC Members may be deemed to share voting, investment and dispositive power over the securities held by Longwood and as a result may be deemed to have beneficial ownership over such securities. Longwood GP and each of the IC Members disclaims beneficial ownership over the securities held by Longwood, except to the extent of their respective pecuniary interests therein.
Voting Common StockSEC Table I · non-derivative	IndirectSee footnote	1,278,838	Reported balance After 2021-07-20 transaction · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · 2021-07-20 · Purchase · Acquired 133,333 · Balance 1,278,838 F4: Represents shares purchased in the Issuer's initial public offering. F3: These shares are held by Longwood Fund IV, L.P. ("Longwood"). The general partner of Longwood is Longwood Fund IV GP, LLC ("Longwood GP"). Voting, investment and dispositive decisions at Longwood GP with respect to the securities held by Longwood are made by an investment committee comprised of Christoph Westphal, Richard Aldrich and John Lawrence (collectively, the "IC Members"). Longwood GP and each of the IC Members may be deemed to share voting, investment and dispositive power over the securities held by Longwood and as a result may be deemed to have beneficial ownership over such securities. Longwood GP and each of the IC Members disclaims beneficial ownership over the securities held by Longwood, except to the extent of their respective pecuniary interests therein.
Voting Common StockSEC Table I · non-derivative	IndirectSee footnote	121,951	Reported balance Holding disclosure · report date 2021-07-20 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 121,951 F1: These shares are held by the Reporting Person's spouse.
Series A Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2021-07-20 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2021-07-20 · Conversion · Disposed 641,848 · Balance 0 F2: Each share of the Issuer's preferred stock automatically converted on a one for one basis into Voting Common Stock immediately prior to the closing of the Issuer's initial public offering, without payment or further consideration. The preferred stock had no expiration date. F3: These shares are held by Longwood Fund IV, L.P. ("Longwood"). The general partner of Longwood is Longwood Fund IV GP, LLC ("Longwood GP"). Voting, investment and dispositive decisions at Longwood GP with respect to the securities held by Longwood are made by an investment committee comprised of Christoph Westphal, Richard Aldrich and John Lawrence (collectively, the "IC Members"). Longwood GP and each of the IC Members may be deemed to share voting, investment and dispositive power over the securities held by Longwood and as a result may be deemed to have beneficial ownership over such securities. Longwood GP and each of the IC Members disclaims beneficial ownership over the securities held by Longwood, except to the extent of their respective pecuniary interests therein.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2021-07-20 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2021-07-20 · Conversion · Disposed 332,594 · Balance 0 F2: Each share of the Issuer's preferred stock automatically converted on a one for one basis into Voting Common Stock immediately prior to the closing of the Issuer's initial public offering, without payment or further consideration. The preferred stock had no expiration date. F3: These shares are held by Longwood Fund IV, L.P. ("Longwood"). The general partner of Longwood is Longwood Fund IV GP, LLC ("Longwood GP"). Voting, investment and dispositive decisions at Longwood GP with respect to the securities held by Longwood are made by an investment committee comprised of Christoph Westphal, Richard Aldrich and John Lawrence (collectively, the "IC Members"). Longwood GP and each of the IC Members may be deemed to share voting, investment and dispositive power over the securities held by Longwood and as a result may be deemed to have beneficial ownership over such securities. Longwood GP and each of the IC Members disclaims beneficial ownership over the securities held by Longwood, except to the extent of their respective pecuniary interests therein.
Series C Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2021-07-20 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2021-07-20 · Conversion · Disposed 171,063 · Balance 0 F2: Each share of the Issuer's preferred stock automatically converted on a one for one basis into Voting Common Stock immediately prior to the closing of the Issuer's initial public offering, without payment or further consideration. The preferred stock had no expiration date. F3: These shares are held by Longwood Fund IV, L.P. ("Longwood"). The general partner of Longwood is Longwood Fund IV GP, LLC ("Longwood GP"). Voting, investment and dispositive decisions at Longwood GP with respect to the securities held by Longwood are made by an investment committee comprised of Christoph Westphal, Richard Aldrich and John Lawrence (collectively, the "IC Members"). Longwood GP and each of the IC Members may be deemed to share voting, investment and dispositive power over the securities held by Longwood and as a result may be deemed to have beneficial ownership over such securities. Longwood GP and each of the IC Members disclaims beneficial ownership over the securities held by Longwood, except to the extent of their respective pecuniary interests therein.
Voting Common StockSEC Table I · non-derivative	Direct	914,634	Reported balance Holding disclosure · report date 2021-07-20 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 914,634

Filing footnotes · ownership attribution and instrument terms

F1: These shares are held by the Reporting Person's spouse.

F2: Each share of the Issuer's preferred stock automatically converted on a one for one basis into Voting Common Stock immediately prior to the closing of the Issuer's initial public offering, without payment or further consideration. The preferred stock had no expiration date.

F3: These shares are held by Longwood Fund IV, L.P. ("Longwood"). The general partner of Longwood is Longwood Fund IV GP, LLC ("Longwood GP"). Voting, investment and dispositive decisions at Longwood GP with respect to the securities held by Longwood are made by an investment committee comprised of Christoph Westphal, Richard Aldrich and John Lawrence (collectively, the "IC Members"). Longwood GP and each of the IC Members may be deemed to share voting, investment and dispositive power over the securities held by Longwood and as a result may be deemed to have beneficial ownership over such securities. Longwood GP and each of the IC Members disclaims beneficial ownership over the securities held by Longwood, except to the extent of their respective pecuniary interests therein.

F4: Represents shares purchased in the Issuer's initial public offering.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Decoy Therapeutics Inc.

Report date December 31, 2017 · Filed December 21, 2018

Section 16 reporting ended · disclosed 2018-12-21. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	3,044,627	Reported balance After 2018-11-06 transaction · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · 2018-11-06 · Gift · Disposed 858,300 · Balance 3,044,627
Common StockSEC Table I · non-derivative	Direct	844,627	Reported balance After 2018-12-20 transaction · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · 2018-12-20 · Gift · Disposed 2,200,000 · Balance 844,627
Common StockSEC Table I · non-derivative	Direct	22,321	Reported balance Holding disclosure · report date 2017-12-31 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 22,321 F1: These shares are held directly by The Christoph H. Westphal Revocable Trust, the Reporting Person is a beneficiary of The Christoph H. Westphal Revocable Trust.
Common StockSEC Table I · non-derivative	Direct	15,870	Reported balance Holding disclosure · report date 2017-12-31 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 15,870 F2: These shares are held directly by The Christoph Westphal Roth IRA, the Reporting Person is a beneficiary of The Christoph Westphal Roth IRA.

Filing footnotes · ownership attribution and instrument terms

F1: These shares are held directly by The Christoph H. Westphal Revocable Trust, the Reporting Person is a beneficiary of The Christoph H. Westphal Revocable Trust.

F2: These shares are held directly by The Christoph Westphal Roth IRA, the Reporting Person is a beneficiary of The Christoph Westphal Roth IRA.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
July 20, 2021 Filed Jul 22, 2021 20:46 UTC	TScan Therapeutics, Inc. TCRX · Entity 7255	ConversionSeries C Preferred Stock · Derivative	171,063	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-21-029479 · doc4.xml · derivative · entry 7 Westphal Christoph H · CIK 0001291961 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Voting Common Stock · 171,063 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of the Issuer's preferred stock automatically converted on a one for one basis into Voting Common Stock immediately prior to the closing of the Issuer's initial public offering, without payment or further consideration. The preferred stock had no expiration date. F2 · price: Each share of the Issuer's preferred stock automatically converted on a one for one basis into Voting Common Stock immediately prior to the closing of the Issuer's initial public offering, without payment or further consideration. The preferred stock had no expiration date. F2 · derivative.exercise_date: Each share of the Issuer's preferred stock automatically converted on a one for one basis into Voting Common Stock immediately prior to the closing of the Issuer's initial public offering, without payment or further consideration. The preferred stock had no expiration date. F2 · derivative.expiration_date: Each share of the Issuer's preferred stock automatically converted on a one for one basis into Voting Common Stock immediately prior to the closing of the Issuer's initial public offering, without payment or further consideration. The preferred stock had no expiration date. F3 · ownership.nature: These shares are held by Longwood Fund IV, L.P. ("Longwood"). The general partner of Longwood is Longwood Fund IV GP, LLC ("Longwood GP"). Voting, investment and dispositive decisions at Longwood GP with respect to the securities held by Longwood are made by an investment committee comprised of Christoph Westphal, Richard Aldrich and John Lawrence (collectively, the "IC Members"). Longwood GP and each of the IC Members may be deemed to share voting, investment and dispositive power over the securities held by Longwood and as a result may be deemed to have beneficial ownership over such securities. Longwood GP and each of the IC Members disclaims beneficial ownership over the securities held by Longwood, except to the extent of their respective pecuniary interests therein. Read SEC document
July 20, 2021 Filed Jul 22, 2021 20:46 UTC	TScan Therapeutics, Inc. TCRX · Entity 7255	ConversionSeries B Preferred Stock · Derivative	332,594	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-21-029479 · doc4.xml · derivative · entry 6 Westphal Christoph H · CIK 0001291961 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Voting Common Stock · 332,594 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of the Issuer's preferred stock automatically converted on a one for one basis into Voting Common Stock immediately prior to the closing of the Issuer's initial public offering, without payment or further consideration. The preferred stock had no expiration date. F2 · price: Each share of the Issuer's preferred stock automatically converted on a one for one basis into Voting Common Stock immediately prior to the closing of the Issuer's initial public offering, without payment or further consideration. The preferred stock had no expiration date. F2 · derivative.exercise_date: Each share of the Issuer's preferred stock automatically converted on a one for one basis into Voting Common Stock immediately prior to the closing of the Issuer's initial public offering, without payment or further consideration. The preferred stock had no expiration date. F2 · derivative.expiration_date: Each share of the Issuer's preferred stock automatically converted on a one for one basis into Voting Common Stock immediately prior to the closing of the Issuer's initial public offering, without payment or further consideration. The preferred stock had no expiration date. F3 · ownership.nature: These shares are held by Longwood Fund IV, L.P. ("Longwood"). The general partner of Longwood is Longwood Fund IV GP, LLC ("Longwood GP"). Voting, investment and dispositive decisions at Longwood GP with respect to the securities held by Longwood are made by an investment committee comprised of Christoph Westphal, Richard Aldrich and John Lawrence (collectively, the "IC Members"). Longwood GP and each of the IC Members may be deemed to share voting, investment and dispositive power over the securities held by Longwood and as a result may be deemed to have beneficial ownership over such securities. Longwood GP and each of the IC Members disclaims beneficial ownership over the securities held by Longwood, except to the extent of their respective pecuniary interests therein. Read SEC document
July 20, 2021 Filed Jul 22, 2021 20:46 UTC	TScan Therapeutics, Inc. TCRX · Entity 7255	ConversionSeries A Preferred Stock · Derivative	641,848	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-21-029479 · doc4.xml · derivative · entry 5 Westphal Christoph H · CIK 0001291961 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Voting Common Stock · 641,848 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of the Issuer's preferred stock automatically converted on a one for one basis into Voting Common Stock immediately prior to the closing of the Issuer's initial public offering, without payment or further consideration. The preferred stock had no expiration date. F2 · price: Each share of the Issuer's preferred stock automatically converted on a one for one basis into Voting Common Stock immediately prior to the closing of the Issuer's initial public offering, without payment or further consideration. The preferred stock had no expiration date. F2 · derivative.exercise_date: Each share of the Issuer's preferred stock automatically converted on a one for one basis into Voting Common Stock immediately prior to the closing of the Issuer's initial public offering, without payment or further consideration. The preferred stock had no expiration date. F2 · derivative.expiration_date: Each share of the Issuer's preferred stock automatically converted on a one for one basis into Voting Common Stock immediately prior to the closing of the Issuer's initial public offering, without payment or further consideration. The preferred stock had no expiration date. F3 · ownership.nature: These shares are held by Longwood Fund IV, L.P. ("Longwood"). The general partner of Longwood is Longwood Fund IV GP, LLC ("Longwood GP"). Voting, investment and dispositive decisions at Longwood GP with respect to the securities held by Longwood are made by an investment committee comprised of Christoph Westphal, Richard Aldrich and John Lawrence (collectively, the "IC Members"). Longwood GP and each of the IC Members may be deemed to share voting, investment and dispositive power over the securities held by Longwood and as a result may be deemed to have beneficial ownership over such securities. Longwood GP and each of the IC Members disclaims beneficial ownership over the securities held by Longwood, except to the extent of their respective pecuniary interests therein. Read SEC document
July 20, 2021 Filed Jul 22, 2021 20:46 UTC	TScan Therapeutics, Inc. TCRX · Entity 7255	PurchaseVoting Common Stock	133,333	$15.00	$1,999,995.00	Disclosure SEC source: 0000899243-21-029479 · doc4.xml · nonDerivative · entry 4 Westphal Christoph H · CIK 0001291961 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,278,838 F4 · shares: Represents shares purchased in the Issuer's initial public offering. F3 · ownership.nature: These shares are held by Longwood Fund IV, L.P. ("Longwood"). The general partner of Longwood is Longwood Fund IV GP, LLC ("Longwood GP"). Voting, investment and dispositive decisions at Longwood GP with respect to the securities held by Longwood are made by an investment committee comprised of Christoph Westphal, Richard Aldrich and John Lawrence (collectively, the "IC Members"). Longwood GP and each of the IC Members may be deemed to share voting, investment and dispositive power over the securities held by Longwood and as a result may be deemed to have beneficial ownership over such securities. Longwood GP and each of the IC Members disclaims beneficial ownership over the securities held by Longwood, except to the extent of their respective pecuniary interests therein. Read SEC document
July 20, 2021 Filed Jul 22, 2021 20:46 UTC	TScan Therapeutics, Inc. TCRX · Entity 7255	ConversionVoting Common Stock	1,145,505	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-21-029479 · doc4.xml · nonDerivative · entry 3 Westphal Christoph H · CIK 0001291961 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,145,505 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each share of the Issuer's preferred stock automatically converted on a one for one basis into Voting Common Stock immediately prior to the closing of the Issuer's initial public offering, without payment or further consideration. The preferred stock had no expiration date. F3 · ownership.nature: These shares are held by Longwood Fund IV, L.P. ("Longwood"). The general partner of Longwood is Longwood Fund IV GP, LLC ("Longwood GP"). Voting, investment and dispositive decisions at Longwood GP with respect to the securities held by Longwood are made by an investment committee comprised of Christoph Westphal, Richard Aldrich and John Lawrence (collectively, the "IC Members"). Longwood GP and each of the IC Members may be deemed to share voting, investment and dispositive power over the securities held by Longwood and as a result may be deemed to have beneficial ownership over such securities. Longwood GP and each of the IC Members disclaims beneficial ownership over the securities held by Longwood, except to the extent of their respective pecuniary interests therein. Read SEC document
December 20, 2018 Filed Dec 21, 2018 17:03 UTC	Decoy Therapeutics Inc. FLKS · Entity 937	GiftCommon Stock	2,200,000	$0.00	$0.00	Disclosure SEC source: 0001104659-18-074495 · a5.xml · nonDerivative · entry 2 Westphal Christoph H · CIK 0001291961 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 844,627 Read SEC document
November 06, 2018 Filed Dec 21, 2018 17:03 UTC	Decoy Therapeutics Inc. FLKS · Entity 937	GiftCommon Stock	858,300	$0.00	$0.00	Disclosure SEC source: 0001104659-18-074495 · a5.xml · nonDerivative · entry 1 Westphal Christoph H · CIK 0001291961 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,044,627 Read SEC document
October 16, 2018 Filed Oct 18, 2018 17:02 UTC	Decoy Therapeutics Inc. FLKS · Entity 937	SaleCommon Stock	3,212,861	$0.92	$2,941,052.96	Disclosure SEC source: 0001104659-18-062807 · a4.xml · nonDerivative · entry 2 Westphal Christoph H · CIK 0001291961 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 0 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.70 to $1.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2 · ownership.nature: No shares were sold by Christoph Westphal, M.D., Ph.D. ("Westphal") in this transaction. Represents 2,697,264 shares sold by Longwood Fund II, L.P. ("Longwood Fund II") and 515,597 shares sold by Longwood Fund III, L.P. ("Longwood Fund III"). Longwood Fund II GP, LLC is the General Partner of Longwood Fund II and Longwood Fund III GP, LLC is the General Partner of Longwood Fund III. The managers of Longwood Fund II GP, LLC and Longwood Fund III GP, LLC (the "Managers") have delegated their voting and dispositive power with respect to the Issuer's securities held by Longwood Fund II and Longwood Fund III (the "Longwood Shares") to a committee comprised of three members, one of which is Westphal (the "Longwood Committee"). F3 · ownership.nature: The Longwood Committee approves investment and voting decisions by a majority vote, and no individual member has sole control or voting power over the Longwood Shares. Each of Westphal, Longwood Fund II GP, LLC, Longwood Fund III GP, LLC, the Managers and the members of the Longwood Committee disclaim beneficial ownership of the Longwood Shares, except to the extent of their respective pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the shares for purposes of Section 16 or for any other purpose. Read SEC document
July 26, 2017 Filed Jul 27, 2017 08:54 UTC	Decoy Therapeutics Inc. FLKS · Entity 937	GrantStock Option (right to buy) · Derivative	12,000	$0.00 Strike: $4.08	$0.00	Disclosure SEC source: 0001615219-17-000056 · wf-form4_150116007433619.xml · derivative · entry 1 Westphal Christoph H · CIK 0001291961 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2027-07-26 F1 · derivative.exercise_date: The stock option will vest in 12 successive equal monthly installments measured from July 26, 2017. Read SEC document
November 08, 2016 Filed Nov 8, 2016 16:23 UTC	Decoy Therapeutics Inc. FLKS · Entity 937	PurchaseCommon Stock	7,000	$7.31	$51,170.00	Disclosure SEC source: 0001615219-16-000232 · wf-form4_147864022091781.xml · nonDerivative · entry 1 Westphal Christoph H · CIK 0001291961 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,941,118 F1 · price: The price in Column 4 is a weighted average purchase price. The prices actually received ranged from $7.30 to $7.32. The reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, information regarding the number of shares purchased at each price within the range. Read SEC document
November 07, 2016 Filed Nov 7, 2016 16:43 UTC	Decoy Therapeutics Inc. FLKS · Entity 937	PurchaseCommon Stock	8,870	$5.70	$50,559.00	Disclosure SEC source: 0001615219-16-000230 · wf-form4_147855499188160.xml · nonDerivative · entry 1 Westphal Christoph H · CIK 0001291961 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,934,118 F1 · price: The price in Column 4 is a weighted average purchase price. The prices actually received ranged from $5.66 to $5.73. The reporting person will provide to the Issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares purchased at each price within the range. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.